• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Leading Independent Proxy Advisory Firm ISS Recommends Avalara Shareholders Vote "FOR" The Transaction With Vista Equity Partners

    9/30/22 3:00:11 PM ET
    $ALVR
    $AVLR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    EDP Services
    Technology
    Get the next $ALVR alert in real time by email

    Avalara Urges Shareholders to Vote "FOR" Value Maximizing Transaction on WHITE Proxy Card

    Avalara, Inc. (NYSE:AVLR), a leading provider of tax compliance automation for businesses of all sizes, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that shareholders vote "FOR" the pending transaction with Vista Equity Partners ("Vista") at the Company's upcoming Special Meeting of Shareholders (the "Special Meeting") scheduled for October 14, 2022.

    In its September 30, 2022, report, ISS noted1:

    • "… the proposed transaction provides certainty of value, at a premium to the unaffected price, compared to the significant downside risk of non-approval and the uncertainty surrounding a potential market recovery."
    • "There is a significant downside risk of non-approval; technology companies that revise guidance and miss earnings are heavily penalized in the current market environment, which amplifies the downside risk. Absent this transaction, it appears that AVLR shares could trade in the mid-to-high $60's per share. There has been a marked decline in valuations of AVLR's peers over the last year, a trend that has continued since the transaction announcement."
    • "There is also significant uncertainty regarding how much time would be needed for some combination of revenue growth, profitability, and multiple expansion to deliver shareholder value that is in line with historic trading levels, given significant macroeconomic impacts including rising interest rates and inflation. These factors raise substantial doubt that shareholders are better served by rejecting the merger."
    • "Nonetheless, when the modest decline in projections is evaluated in concert with the decline in valuation multiples for AVLR and its peers, and taking into account the company's anticipated challenges, the expected underperformance appears to support the board's argument that the present moment is an appropriate one to sell the company."

    The Company is pleased that ISS shares its belief that the transaction with Vista is in the best interests of all Avalara shareholders and supports the Board's unanimous recommendation that shareholders vote FOR the transaction. The transaction with Vista delivers significant, immediate, and certain value to shareholders, eliminating shareholders' exposure to the execution risks and significant macroeconomic headwinds associated with continuing as a standalone company. The Company strongly urges all Avalara shareholders to follow the recommendation of ISS by voting "FOR" the value maximizing transaction with Vista on the WHITE proxy card today to receive $93.50 per share in cash.

    The transaction is expected to close in the second half of 2022, subject to customary closing conditions, including approval by Avalara shareholders.

    Avalara shareholders who need assistance in voting their shares may call toll-free Avalara's proxy solicitor, Innisfree M&A Incorporated, at (877) 687-1873 (U.S. or Canada) or +1 (412) 232-3651 (international).

    A special meeting of Avalara's shareholders to be held virtually in connection with the proposed merger on October 14, 2022, at 9:00 a.m., Eastern Time. Shareholders will be able to attend the meeting by visiting www.cesonlineservices.com/avlr22_vm, where they will be able to listen to the special meeting, submit questions, and vote. To participate in the special meeting, shareholders must pre-register at www.cesonlineservices.com/avlr22_vm by 9:00 a.m., Eastern Time on Thursday, October 13, 2022. Shareholders will not be able to attend the meeting in person.

    Get the next $ALVR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALVR
    $AVLR

    CompanyDatePrice TargetRatingAnalyst
    AlloVir Inc.
    $ALVR
    12/26/2023$17.00 → $1.00Buy → Underperform
    BofA Securities
    AlloVir Inc.
    $ALVR
    12/22/2023Outperform → Market Perform
    Leerink Partners
    AlloVir Inc.
    $ALVR
    12/22/2023Overweight → Underweight
    JP Morgan
    AlloVir Inc.
    $ALVR
    12/22/2023Overweight → Neutral
    Piper Sandler
    AlloVir Inc.
    $ALVR
    8/18/2023$17.00Buy
    BofA Securities
    Avalara Inc.
    $AVLR
    8/29/2022Mkt Outperform → Mkt Perform
    JMP Securities
    Avalara Inc.
    $AVLR
    8/16/2022$111.00 → $93.50Overweight → Equal-Weight
    Morgan Stanley
    Avalara Inc.
    $AVLR
    8/15/2022Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $ALVR
    $AVLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Hagen Brett R sold $8,135 worth of shares (907 units at $8.97), decreasing direct ownership by 32% to 1,925 units (SEC Form 4)

    4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

    3/27/25 7:19:58 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: New insider Akkaraju Srinivas claimed ownership of 3,578 shares (SEC Form 3)

    3/A - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

    3/26/25 5:06:57 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Samsara Biocapital Gp, Llc claimed ownership of 11,448,081 shares (SEC Form 3)

    3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

    3/25/25 7:38:53 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVR
    $AVLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AlloVir downgraded by BofA Securities with a new price target

    BofA Securities downgraded AlloVir from Buy to Underperform and set a new price target of $1.00 from $17.00 previously

    12/26/23 7:17:53 AM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AlloVir downgraded by Leerink Partners

    Leerink Partners downgraded AlloVir from Outperform to Market Perform

    12/22/23 10:47:30 AM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AlloVir downgraded by JP Morgan

    JP Morgan downgraded AlloVir from Overweight to Underweight

    12/22/23 9:11:15 AM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVR
    $AVLR
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by AlloVir Inc.

    SCHEDULE 13D - Kalaris Therapeutics, Inc. (0001754068) (Subject)

    3/25/25 7:40:09 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by AlloVir Inc.

    SCHEDULE 13G/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)

    3/20/25 4:32:25 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AlloVir Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Leadership Update, Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Regulation FD Disclosure

    8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)

    3/18/25 5:04:06 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVR
    $AVLR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Five9 Appoints Amit Mathradas as Next Chief Executive Officer

    Mathradas Brings a Track Record of AI Product Innovation and Delivering Operational Excellence at Scale Succeeds Long-Time CEO Mike Burkland, Who Will Remain on Board of Directors to Ensure Smooth Transition Five9, Inc. (NASDAQ:FIVN) ("Five9" or the "Company"), provider of the Intelligent CX Platform, today announced that its Board of Directors (the "Board") has appointed Amit Mathradas as the Company's Chief Executive Officer ("CEO") and a director, effective February 2, 2026. Mr. Mathradas will take on the role from Board Chairman Mike Burkland, whose decision to retire from the CEO position was announced in July. Mr. Burkland will continue to serve on the Board and will work with Mr. M

    12/17/25 8:30:00 AM ET
    $FIVN
    $AVLR
    EDP Services
    Technology

    AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

    3/4/24 5:37:52 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

    2/28/24 1:06:25 AM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVR
    $AVLR
    Leadership Updates

    Live Leadership Updates

    View All

    Five9 Appoints Amit Mathradas as Next Chief Executive Officer

    Mathradas Brings a Track Record of AI Product Innovation and Delivering Operational Excellence at Scale Succeeds Long-Time CEO Mike Burkland, Who Will Remain on Board of Directors to Ensure Smooth Transition Five9, Inc. (NASDAQ:FIVN) ("Five9" or the "Company"), provider of the Intelligent CX Platform, today announced that its Board of Directors (the "Board") has appointed Amit Mathradas as the Company's Chief Executive Officer ("CEO") and a director, effective February 2, 2026. Mr. Mathradas will take on the role from Board Chairman Mike Burkland, whose decision to retire from the CEO position was announced in July. Mr. Burkland will continue to serve on the Board and will work with Mr. M

    12/17/25 8:30:00 AM ET
    $FIVN
    $AVLR
    EDP Services
    Technology

    AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

    3/4/24 5:37:52 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

    2/28/24 1:06:25 AM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVR
    $AVLR
    Financials

    Live finance-specific insights

    View All

    Avalara Announces Second Quarter 2022 Financial Results

    Company Cancels Earnings Call in Light of Transaction with Vista Equity Partners Second Quarter Total Revenue of $208.6 Million Total Revenue Growth of 23% From Second Quarter 2021 Avalara, Inc. (NYSE:AVLR), a leading provider of tax compliance automation for businesses of all sizes, today announced financial results for its second quarter ended June 30, 2022. "We posted a solid second quarter delivering year-over-year total revenue growth of 23%, in line with our guidance and we outperformed on our operating income guidance. We remain focused on delivering on the 2025 growth and profitability targets that we laid out at our recent Investor Day," said Scott McFarlane, Avalara co-founder

    8/8/22 7:01:00 AM ET
    $AVLR
    EDP Services
    Technology

    Avalara to Announce Second Quarter 2022 Financial Results on August 8, 2022

    Avalara, Inc. (NYSE:AVLR), a leading provider of tax compliance automation for businesses of all sizes, today announced that it will report financial results for its second quarter ended June 30, 2022 on Monday, August 8, 2022 after market close. Avalara will host a conference call and webcast at 2:00 p.m. Pacific Time (or 5:00 p.m. Eastern Time) on the same day to discuss its financial results and business highlights. Avalara Second Quarter 2022 Earnings Conference Call When: Monday, August 8, 2022 Time: 2:00 p.m. PT (5:00 p.m. ET) Conference Call: (888) 660-6196 from the United States, (929) 203-1824 International, with Conference ID 5816067; please dial in at least 15 minutes prio

    7/20/22 4:10:00 PM ET
    $AVLR
    EDP Services
    Technology

    Avalara Announces First Quarter 2022 Financial Results

    First Quarter Total Revenue of $204.5 Million Total Revenue Growth of 33% From First Quarter 2021 Avalara, Inc. (NYSE:AVLR), a leading provider of tax compliance automation for businesses of all sizes, today announced financial results for its first quarter ended March 31, 2022. "We started 2022 with another strong quarter, exceeding our guidance and achieving topline revenue growth of 33% year-over-year," said Scott McFarlane, Avalara co-founder and chief executive officer. "Mounting complexity in today's digital-first world is pushing global demand for compliance automation. We continue to execute our strategy to build the global cloud compliance platform to achieve our vision of being

    5/5/22 4:10:00 PM ET
    $AVLR
    EDP Services
    Technology

    $ALVR
    $AVLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by AlloVir Inc.

    SC 13G - Allovir, Inc. (0001754068) (Subject)

    10/11/24 4:02:13 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by AlloVir Inc.

    SC 13G/A - Allovir, Inc. (0001754068) (Subject)

    8/2/24 6:25:25 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by AlloVir Inc. (Amendment)

    SC 13G/A - Allovir, Inc. (0001754068) (Subject)

    2/13/24 4:54:00 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care